Milltrust International is proud to be supporting the British Innovation Fund‘s investee company Attomarker Ltd in the fight against Covid-19 testing currently underway at St Thomas’s Hospital in London.
Milltrust is seeking to close a funding round of £5m (extended Series A) in the coming months ahead of £15-50m (Series B) to follow after.
Attomarker technology will allow a rapid test for antibodies in the patient’s blood to five surface antigens and a simultaneous measurement of the inflammatory biomarker, C-reactive protein. The results of each individual test will be available in around five minutes. If successful, we will be able to answer the following questions about the patient:
• Is the patient sick and raising an immune response to the virus?
• Is the patient’s immune response going to be protective?
• Has the patient recovered, no longer sick but protected?
Professor Shaw is working in collaboration with Professor Chris Hyde of the Exeter Medical School and Professor Jonathan Edgeworth at St Thomas’s Hospital Centre for Clinical Infection and Diagnostics. This latter is one of the technology assessment centres contributing to the government’s response to the pandemic.
Download Presentation: https://www.milltrust.com/wp-content/uploads/2020.2Q-Attomarker-Intro-Deck.pdf
Attomarker has launched a new, simple to use, point-of-care blood testing device that can perform up to eight simultaneous tests from a single pin-prick of blood in less than 5 minutes. The patented Attomarker technology uses a disposable credit-card sized chip that slots into a handheld device docked to an iPhone that provides rapid testing for the healthcare professional and the consumer markets. Attomarker was selected as a candidate for the Longitude Prize, a 10 million GBP award in the fight against anti-microbial resistance. It is now part of a permanent exhibition at the Science Museum in London. Work has begun at the behest of the UK Government to develop a test for coronavirus, as well as a proposal for TB in urine and blood – this will be mixed with HIV.
About Milltrust International Group
With a unique multi-local multi-affiliate structure, Milltrust provides innovative investment solutions where we can offer genuinely differentiated alpha to our investors around the globe. The firm operates in a regulated capacity across multiple jurisdictions including the UK, Singapore, Ireland, Cayman, and Mauritius. The primary affiliated businesses are: Milltrust International LLP and Milltrust Agricultural Investments.
About The British Innovation Fund
The British Innovation Fund recognises the world-class science and technology development that is being carried out in many of Britain’s top universities. The Fund nurtures impactful, early-stage companies –helping them reach their full potential and guiding them to worldwide recognition and success.
The Fund carefully picks spin-out companies from the established, in-house university commercialisation companies which the Fund has invested in – spin-out companies that demonstrate a viable commercial business and are already generating revenue. This significantly reduces investment risks and enhances the probability of outsized returns for investors.
Download Presentation: https://www.milltrust.com/wp-content/uploads/2020.02-BIF-presentation-Feb-20.pdf
Contact Us: [email protected]
For professional investors only. This document is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International Group (Singapore) Pte Ltd, incorporated in Singapore. Milltrust International LLP is incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Agricultural Investments Ltd is an affiliate of Milltrust International LLP. The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International Group (Singapore) Pte Ltd or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not creat1e a fiduciary relationship between such person and Milltrust International Group (Singapore) Pte Ltd. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this document before making any decisions based on such information or other content rests with the user and their professional advisers.